Last week, our team attended ICONAN 2026, the Nanomedicine and Nanobiotechnology meeting held in Rome, where we presented our latest progress in the development of next-generation tumor-targeted nanoconjugates for targeted drug delivery in cancer. Presenting at ICONAN provided an excellent opportunity to discuss our approach with leading groups in the field and receive valuable feedback.
